Brief: Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer
05/08/2026 13:17
BRIEF-Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer Aug 5 (Reuters) - Summit Therapeutics Inc. SMMT.O:
SUMMIT THERAPEUTICS - INITIATES GLOBAL PHASE II/III HARMONI-GU1 TRIAL OF IVONESCIMAB IN BLADDER CANCER
Source text: ID:nBw7Q5fSfa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)